Upload File

The top documents tagged [treatmentnave patients]

2010 Guidelines Case Study #1 Mrs. DT 2010 Guidelines
2010 Guidelines Case Study #1 Mrs. DT 2010 Guidelines
225 views
Using genetic markers in clinical practice David Thomas Advisor: Merck Clinical trial: Gilead and Merck
Using genetic markers in clinical practice David Thomas Advisor: Merck Clinical trial: Gilead and Merck
215 views
Boceprevir Combined with Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patients with HCV Genotype 1 SPRINT-2 Final Results Mark S. Sulkowski, Fred
Boceprevir Combined with Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patients with HCV Genotype 1 SPRINT-2 Final Results Mark S. Sulkowski, Fred
215 views
HIV and Aging: a Time for a New Paradigm Amy C. Justice, MD, MSCE, PhD Professor, Yale University Section Chief, General Internal Medicine VA Connecticut
HIV and Aging: a Time for a New Paradigm Amy C. Justice, MD, MSCE, PhD Professor, Yale University Section Chief, General Internal Medicine VA Connecticut
213 views
1 This activity has been supported by an independent medical education grant from Bristol Myers Squibb. 2013 IC-HEP Educational supporters include Bristol
1 This activity has been supported by an independent medical education grant from Bristol Myers Squibb. 2013 IC-HEP Educational supporters include Bristol
216 views
Hepatitis web study Hepatitis web study Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT-1 ELECTRON Trial (Arms 12-17 & 22) Phase 2 Treatment Naïve
Hepatitis web study Hepatitis web study Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT-1 ELECTRON Trial (Arms 12-17 & 22) Phase 2 Treatment Naïve
214 views
Practitioner’s Edge is a registered service mark of Integrity Continuing Education, Inc. © 2014 Integrity Continuing Education, Inc. Sponsored by Integrity
Practitioner’s Edge is a registered service mark of Integrity Continuing Education, Inc. © 2014 Integrity Continuing Education, Inc. Sponsored by Integrity
220 views
CER Institute - Clinical Research
CER Institute - Clinical Research
284 views
Highlights from CROI 18th Conference on Retroviruses and Opportunistic Infections Boston, MA February 28 to March 3, 2011 Iván Meléndez-Rivera, MD Assistant
Highlights from CROI 18th Conference on Retroviruses and Opportunistic Infections Boston, MA February 28 to March 3, 2011 Iván Meléndez-Rivera, MD Assistant
219 views
CONFIDENTIAL Investor Call December 9, 2010 Claire L. Kruger, Ph.D., Chief Executive Officer Robert A. Lodder, Ph.D., President
CONFIDENTIAL Investor Call December 9, 2010 Claire L. Kruger, Ph.D., Chief Executive Officer Robert A. Lodder, Ph.D., President
216 views
N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director,
N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director,
219 views
48-week results of once-daily maraviroc (MVC) 150 mg in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine/tenofovir (FTC/TDF)
48-week results of once-daily maraviroc (MVC) 150 mg in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine/tenofovir (FTC/TDF)
213 views